top of page
  • Active, not recruiting
    • Dec 7, 2011

NCT01346787: EMN - Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone Newly Diagnosed Myeloma

Updated: Sep 25, 2022

EMN

European Myeloma Network

NCT01346787: Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (CCD)

ccd myeloma emn

The purpose of this study is to determine whether the association of Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) as induction treatment is safe and provides benefits in patients with newly diagnosed Multiple Myeloma (MM).


Sponsor

European Myeloma Network


Collaborator

Fondazione EMN Italy Onlus

 

ClinicalTrials.gov Identifier: NCT01346787

Official Title: A MULTICENTER, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

IST-CAR-506

First Posted : May 3, 2011

Click here for details on ClinicalTrials.gov